Stifel maintains Zimmer Biomet Holdings at Buy, raises price target to $140 from $125

Stifel kept its Buy rating on Zimmer Biomet Holdings and increased its price target to $140 from $125, suggesting a 35.6% upside from the Nov 13 close of $103.21. Recent analyst targets for the company range from $115 to $130.

Original reporting
Published Nov 16, 2026, 12:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stifel maintains Zimmer Biomet Holdings at Buy, raises price target to $140 from $125 — source image
Decision brief

The 30-second read

$ZBHBullishMed
01

Why it matters

The upgrade may prompt short covering and new buying, modestly lifting the stock.

02

Market read

A single analyst upgrade; modest relevance for traders watching the stock.

03

What to watch

Potential supply chain constraints or regulatory issues not addressed in the note.

Relevance 6/10Novelty 6/10Timing: today

Background

Stifel's analyst note updates the price target for Zimmer Biomet Holdings, a mid‑cap orthopedic device maker.

Company-level read

Ticker impact

$ZBHBullishHigh confidence
Context

Stifel raised its price target for Zimmer Biomet Holdings to $140 from $125, indicating a bullish outlook.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

The new target implies a 35.6% upside from the recent close, which may attract buying interest.

Market effects

May lift sentiment in the orthopedic device sector.

Limited to U.S. equities, no broader regional effect.

Minimal global impact beyond sector peers.

Counterpoint

Target raise could be premature if upcoming earnings miss expectations.

Key entities

  • Stifel

    Provided the upgraded price target.

  • Zimmer Biomet Holdings

    Subject of the analyst rating change.

Related articles

$ZBHMed

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.

$ZBHMed

Truist raises Zimmer Biomet stock price target on robotics progress

Truist Securities raised Zimmer Biomet's (ZBH) price target to $114 from $106, citing 3.7% Q3 organic revenue growth, though EPS missed estimates. The stock is up 13% in a week. Analysts note progress in robotics and hip segments, but caution on knee division weakness and future risks. Other analysts also raised targets, with Stifel at $125 and Jefferies at $120.

$ZBHMed

Zimmer Biomet Holdings Inc (ZBH) (Q3 2026) Earnings Call Highlights: Guidance Raised as Hips

Zimmer Biomet (ZBH) reported Q3 2026 earnings, raising guidance despite a 2.6% decline in knee business due to sales force transition and competitive pressure. Adjusted operating margin fell 140 basis points to 25.1%, and gross margin decreased 90 basis points to 71.7%. CEO Ivan Tornos highlighted sustainable growth in hips and S.E.T. areas, but acknowledged underperformance in knees. China headwinds and sales force disruption pose risks.